Dual-hormone artificial pancreas: benefits and limitations compared with single-hormone systems

Area of Science:

• Biomedical Engineering
• Endocrinology
• Diabetes Technology

Background:

• Artificial pancreas (AP) systems offer improved glucose control and quality of life for individuals with type 1 diabetes.
• Both single-hormone (insulin-only) and dual-hormone (insulin and glucagon) AP systems have been developed.
• A direct comparison of the benefits of single- versus dual-hormone AP systems is needed.

Purpose of the Study:

• To review and compare the efficacy of single- and dual-hormone artificial pancreas systems.
• To evaluate their effectiveness in preventing hypoglycemia and maintaining glycemic control.
• To assess their utility during exercise, overnight, and prandial periods.

Main Methods:

• Systematic review of studies directly comparing single- and dual-hormone artificial pancreas systems.
• Analysis of efficacy in preventing hypoglycemia and maintaining glycemic control.
• Evaluation of performance in specific scenarios: exercise, overnight, and prandial periods.

Main Results:

• Dual-hormone AP systems demonstrated additional benefits in reducing overall hypoglycemia risk and exercise-induced hypoglycemia.
• Single-hormone AP systems were sufficient for overnight euglycemia and preventing late-onset post-exercise hypoglycemia.
• No significant difference was observed in mean glucose control between the systems in the reviewed studies.

Conclusions:

• Dual-hormone AP systems provide enhanced protection against hypoglycemia, particularly during physical activity.
• Single-hormone AP systems are effective for overnight glucose management and preventing delayed post-exercise hypoglycemia.
• Longer-term comparative studies are necessary to determine the superiority of either system for overall glycemic control and quality of life.